Saturday 17 October 2026
Export MDGL’s income statement to Excel — free account
Madrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024. In the quarter to June 2026, revenue grew 71.2%, EPS fell 32.9%, free cash flow grew 140.5% and total debt rose 187.9%, each against the same quarter a year earlier.
449.74
10.07
−2.19%
Follow MDGL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
13.92 | 13.63 | 13.42 | 12.19 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
129.14 | (97.89) | (90.77) | 670.81 | |
P/B ratio |
16.48 | 21.68 | 27.96 | 29.88 | |
Price to Tangible BV |
16.68 | 21.95 | 28.34 | 30.30 | |
EV/Sales |
12.88 | 12.95 | 13.00 | 11.80 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(59.39) | (65.50) | (54.90) | (76.63) | |
EV/FCF |
(57.61) | (64.00) | (53.41) | (72.40) | |
Quick Ratio |
3.14 | 3.62 | 2.97 | 2.76 | |
Current Ratio |
3.44 | 4.01 | 3.50 | 3.20 | |
Net Debt/EBITDA |
6.94 | 11.34 | 5.22 | 9.09 | |
Debt/Assets |
24.94% | 26.98% | 27.73% | 27.38% | |
Debt/Equity |
0.54 | 0.56 | 0.63 | 0.65 | |
Asset Turnover |
0.61 | 0.83 | 1.02 | 1.14 | |
Operating CF/Net income |
(0.70) | 2.28 | 1.77 | (0.40) | |
Capex/Depreciation |
(1.72) | 0.16 | (3.10) | (2.85) | |
Interest Coverage |
(15.30) | (7.18) | (11.86) | (7.09) | |
Research and Development Expense of Revenue |
60.57% | 36.21% | 34.91% | 25.03% | |
Selling, General and Administrative Expense of Revenue |
72.80% | 74.74% | 86.25% | 79.44% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
9.14% | 8.03% | 10.93% | 9.71% | |
Graham Net Nets |
0.06 | 0.05 | 0.03 | 0.03 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.59%) | (2.02%) | (2.37%) | (2.40%) | |
Free Cash Flow Yield |
(1.61%) | (1.48%) | (1.81%) | (1.34%) | |
Revenue per Share |
12.78 | 14.31 | 10.72 | 12.50 | |
Operating CF per Share |
3.55 | (5.95) | (5.77) | 0.80 | |
Capex per Share |
(0.17) | 0.02 | (0.13) | (0.15) | |
Free Cash Flow per Share |
3.38 | (5.93) | (5.90) | 0.65 | |
Cash per Share |
49.58 | 44.07 | 28.17 | 28.78 | |
Shareholders Equity per Share |
27.83 | 26.87 | 18.72 | 17.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
27.83 | 26.87 | 18.72 | 17.97 | |
Free Cash Flow |
75.99 | (133.07) | (171.28) | 19.08 | |
Working Capital |
955.27 | 935.48 | 844.05 | 824.98 | |
Capital Expenditures |
(3.86) | 0.39 | (3.85) | (4.25) | |
Net Current Asset Value |
609.96 | 588.87 | 498.43 | 478.26 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
71.87 | 94.15 | 124.39 | 135.77 | |
Average Payables |
45.45 | 46.24 | 51.43 | 36.24 | |
Average Inventory |
39.02 | 54.45 | 83.66 | 81.44 | |
Average Assets |
1,217.86 | 1,150.92 | 1,111.98 | 1,130.01 | |
Average Common Equity |
701.44 | 678.54 | 627.05 | 609.85 |
Columns are period end dates